Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Lysyl oxidase-like 2 contributes to fibrogenesis by catalyzing cross-linkage of collagen. We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody against lysyl oxidase-like 2, in two phase 2b trials of patients with advanced fibrosis caused by nonalcoholic steatohepatitis.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Gastroenterology

Title: Gastroenterology

Publisher: Elsevier BV

ISSN (Electronic): 1528-0012

ISSN (Print): 0016-5085

Publication date (Electronic): October 2018

Volume: 155

Issue: 4

Affiliations

[1 ] Pinnacle Clinical Research, San Antonio, Texas. Electronic address: sharrison@pinnacleresearch.com.

[2 ] Duke Clinical Research Institute, Durham, North Carolina.

[3 ] University of Virginia, Charlottesville, Virginia.

[4 ] Liver Institute of Virginia, Richmond, Virginia.

[5 ] Texas Clinical Research Institute, Arlington, Texas.

[6 ] Texas Liver Institute, University of Texas Health San Antonio, San Antonio, Texas.

[7 ] Medical University of South Carolina, Charleston, South Carolina.

[8 ] Gilead Sciences, Inc, Foster City, California.

[9 ] Inova Fairfax Hospital, Falls Church, Virginia.

[10 ] Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.

[11 ] Hôpital Pitié-Salpêtrière, Paris, France.

[12 ] Inselspital, Bern University, Switzerland; IDIBAPS, University of Barcelona, Barcelona, Spain.

[13 ] Virginia Commonwealth University, Richmond, Virginia.

Article

Publisher Item ID: S0016-5085(18)34758-9

DOI: 10.1053/j.gastro.2018.07.006

PubMed ID: 29990488

SO-VID: 4c82cdb7-cebb-4f55-9f44-1844fc20c893

History

Keywords: Elastin,Portal Hypertension,Nonalcoholic Fatty Liver Disease,Collagen

Data availability:

Keywords: Elastin, Portal Hypertension, Nonalcoholic Fatty Liver Disease, Collagen

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.

Read this article at

Abstract

Related collections

Karger: Gastroenterology

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 8

Cited by 140